Back to Main

Faculty Detail    
Campus Address CIRC 552 Zip 0021
Phone 205-996-7697
Other websites West laboratory

Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Neurology   Neurology Chair Office Associate Professor
Secondary  Neurobiology  Neurobiology Assistant Professor
Center  Neurology   Alzheimer's Disease Center Associate Professor
Center  Comprehensive Ctr for Healthy Aging  Comprehensive Ctr for Healthy Aging Associate Professor
Center  General Clinical Research Center  Comprehensive Neuroscience Center Associate Professor
Center  General Clinical Research Center  Ctr for Clinical & Translational Sci Associate Professor
Center  Ctr for Glial Bio in Med  Ctr for Glial Bio in Med Associate Professor
Center  Neurology   Ctr Neurodegeneration & Exp Ther (CNET) Associate Professor
Center  General Clinical Research Center  Nephrology Research & Training Center Associate Professor

Graduate Biomedical Sciences Affiliations
Cell, Molecular, & Developmental Biology 
Cellular and Molecular Biology Program 
Genetics and Genomic Sciences 
Medical Scientist Training Program 

Biographical Sketch 
Andrew West, Ph.D. is an Associate Professor of Neurology and holds the John A. and Ruth R. Jurenko Endowed Professorship in Neurology. Dr. West received his undergraduate degree from Alma College and his PhD in Molecular Neuroscience from the Mayo Clinic School of Medicine in Rochester, MN. He then went on to complete a Postdoctoral Fellowship at UCLA Neuropsychiatric Institute in Los Angeles in the laboratory of Nigel Maidment and a second postdoctoral fellowship in the laboratory of Ted Dawson at Johns Hopkins, followed by an Instructor faculty position in the Department of Neurology at Johns Hopkins.

Society Memberships
Organization Name Position Held Org Link
Society for Neuroscience     

Research/Clinical Interest
Genetic and biochemical mechanisms in neurological disorders
Our primary goal is to utilize emerging genetic and genomic approaches to help understand the molecular basis of neurological disorders and develop targeted therapeutic strategies. The laboratory has a major focus on the new and exciting molecule recently discovered as a major cause of familial Parkinson's disease, the LRRK2 protein kinase. We have developed innovative biochemical approaches over the last few years that demonstrate that this kinase may be overactive in Parkinson's disease, and therapeutic approaches to knockdown this activity may provide neuroprotective benefit to Parkinson's disease patients. We are vested in all aspects of pursuing this protein as a drug target, including biomarker assays, antibody and transgenic animal development, and discovery of specific compounds that modify LRRK2 activity together with our collaborators in the pharmaceutical industry. An emerging area of interest in the laboratory is to help contribute to the understanding of autism and identification of new genetic-based models and therapeutic strategies. Our laboratory has assembled together one of the largest collections of post-mortem brain material and is analyzing this material using state of the art genetic approaches including RNAseq and whole genome resequencing, together with collaborators. In addition, we are developing new mouse models of autism based on our discoveries in the pathological tissue.

Selected Publications 
Publication PUBMEDID
West Lab Publications

Alves da Costa C, Sunyach C, Giaime E, West AB, Corti O, Brice A, Abou-Sleiman, P, Wood N, Takahashi H, Goldberg M, Shen J, Checler, F. “Transcriptional repression of p53 by parkin and impairment by autosomal recessive juvenile Parkinson’s disease-associated mutations” Nat Cell Biol. 2009 Oct 4. PMID: 19801972
Dawson TM, Moore DJ, West AB. “Revelations and revolutions in the understanding of Parkinson's disease.” Biochim Biophys Acta. 2009 Jul;1792(7):585-6
Weiss L.A. and the Autism Consortium (…, West AB.,…). “A Genome-wide linkage and Association Scan Reveals Novel Loci for Autism” Nature. 2009 Oct 8;461(7265):802-8. PMID: 19812673
Sen, S., Webber, P., West, AB. “Leucine-rich Repeat Kinase 2 (LRRK2) Kinase Activity: Dependence on Dimerization” J Biol Chem 2009, Oct 13. PMID: 19826009
Webber, P., West, AB. “LRRK2 in Parkinson's disease: function in cells and neurodegeneration.” FEBS J. 2009 Oct 5. PMID: 19804415
Sen S, West AB. “The Therapeutic Potential of LRRK2 and Alpha-synuclein in Parkinson's Disease.” Antioxid Redox Signal. 2009 Mar 9
Aasly JO, Vilariño-Güell C, Dachsel JC, Webber PJ, West AB, Haugarvoll K, Johansen KK, Toft M, Nutt JG, Payami H, Kachergus JM, Lincoln SJ, Felic A, Wider C, Soto-Ortolaza AI, Cobb SA, White LR, Ross OA, Farrer MJ. “Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.” Mov Disord. 2010 Jul 28
Lee BD, Shin JH, Vankampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, Dawson VL, Dawson TM. “Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.” Nat Med. 2010 Aug 22
Pungaliya PP, Bai Y, Lipinski K, Anand VS, Sen S, Brown EL, Bates B, Reinhart PH, West AB, Hirst WD, Braithwaite SP. “Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif.” PLoS One. 2010 Oct 27;5(10):e13672.
Looyenga, B., Furge, K, Dykema, K, Koeman, J, West, AB., Teh, B, Resau, J., Giordano, T., MacKeigan, J. "Chromosomal Amplification of LRRK2 is Required for Oncogenic MET Signaling in Papillary Renal and Thyroid Carcinomas." Proc Natl Acad Sci U S A, 2011 Jan 25;108(4):1439-44
Andrabi SA, Kang HC, Haince JF, Lee YI, Zhang J, Chi Z, West AB, Koehler RC, Poirier GG, Dawson TM, Dawson VL. “Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death.” Nat Med. 2011 May 22
Webber PJ, Smith AD, Sen S, Renfrow MB, Mobley JA, West AB. “Autophosphorylation in the Leucine-Rich Repeat Kinase 2 (LRRK2) GTPase Domain Modifies Kinase and GTP-Binding Activities.” J Mol Biol. 2011 Jul 22
Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, Cowell RM, West AB. “LRRK2 Inhibition Attenuates Microglial Inflammatory Responses” J Neurosci. 2012 Feb 1;32(5):1602-11.
Stafa, K, Trancikova, A., Webber, PJ, Glauser, L., West, AB, Moore, DJ. “'GTPase Activity and Neuronal Toxicity of Parkinson's Disease-Associated LRRK2 is Regulated by ArfGAP1” PLoS Genet. 2012 Feb;8(2):e1002526. Epub 2012 Feb 9.
Trancikova A, Mamais A, Webber PJ, Stafa K, Tsika E, Glauser L, West AB, Bandopadhyay R, Moore DJ. “Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations.” PLoS One. 2012;7(10):e47784 

Molecular Genetics & Disease; Neurobiology